TriSalus Life Sciences, Inc. (TLSI) Research

TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.

Market snapshot

Symbol
TLSI
Price
$4.08
Day change
+4.88%
Market cap
$154.7M
P/E ratio
-7.70x
52-week range
2.2-7.95
Sector
Healthcare
Industry
Medical - Devices
Next earnings
in 2 months
Analyst price target
$8.00

Peer companies

  • Armata Pharmaceuticals, Inc. (ARMP)
  • Anteris Technologies Global Corp. (AVR)
  • Perspective Therapeutics, Inc. (CATX)
  • LENSAR, Inc. (LNSR)
  • MaxCyte, Inc. (MXCT)
  • Nano-X Imaging Ltd. (NNOX)
  • Owlet, Inc. (OWLT)
  • Prenetics Global Limited (PRE)

Recent insider activity

  • Marshak Richard — S-Sale (543 shares) on 2026-05-15
  • Wahlstrom Mats — P-Purchase (60000 shares) on 2026-05-15
  • Stansky Michael P — P-Purchase (410000 shares) on 2026-05-15
  • Stansky Michael P — P-Purchase (200000 shares) on 2026-05-15
  • Szela Mary T — P-Purchase (39682 shares) on 2026-05-15

Open TriSalus Life Sciences, Inc. (TLSI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.